Srivichaivejvivat Past Earnings Performance
Past criteria checks 2/6
Srivichaivejvivat has been growing earnings at an average annual rate of 22.8%, while the Healthcare industry saw earnings growing at 20.9% annually. Revenues have been growing at an average rate of 9.3% per year. Srivichaivejvivat's return on equity is 9.4%, and it has net margins of 10.3%.
Key information
22.8%
Earnings growth rate
22.8%
EPS growth rate
| Healthcare Industry Growth | 23.6% |
| Revenue growth rate | 9.3% |
| Return on equity | 9.4% |
| Net Margin | 10.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Srivichaivejvivat makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,761 | 284 | 337 | 0 |
| 30 Sep 23 | 2,673 | 248 | 336 | 0 |
| 30 Jun 23 | 2,677 | 252 | 349 | 0 |
| 31 Mar 23 | 2,970 | 363 | 389 | 0 |
| 31 Dec 22 | 3,662 | 697 | 417 | 0 |
| 30 Sep 22 | 3,754 | 694 | 439 | 0 |
| 30 Jun 22 | 5,181 | 1,461 | 500 | 0 |
| 31 Mar 22 | 5,394 | 1,565 | 471 | 0 |
| 31 Dec 21 | 4,730 | 1,255 | 432 | 0 |
| 30 Sep 21 | 4,551 | 1,260 | 385 | 0 |
| 30 Jun 21 | 2,980 | 462 | 304 | 0 |
| 31 Mar 21 | 2,320 | 203 | 292 | 0 |
| 31 Dec 20 | 2,290 | 186 | 313 | 0 |
| 30 Sep 20 | 2,331 | 177 | 329 | 0 |
| 30 Jun 20 | 2,438 | 201 | 343 | 0 |
| 31 Mar 20 | 2,537 | 208 | 361 | 0 |
| 31 Dec 19 | 2,503 | 200 | 356 | 0 |
| 30 Sep 19 | 2,417 | 169 | 351 | 0 |
| 30 Jun 19 | 2,330 | 155 | 338 | 0 |
| 31 Mar 19 | 2,282 | 170 | 322 | 0 |
| 31 Dec 18 | 2,259 | 176 | 312 | 0 |
| 30 Sep 18 | 2,225 | 181 | 292 | 0 |
| 30 Jun 18 | 2,146 | 162 | 286 | 0 |
| 31 Mar 18 | 2,081 | 145 | 282 | 0 |
| 31 Dec 17 | 1,974 | 125 | 274 | 0 |
| 30 Sep 17 | 1,917 | 116 | 283 | 0 |
| 30 Jun 17 | 1,879 | 119 | 277 | 0 |
| 31 Mar 17 | 1,809 | 137 | 263 | 0 |
| 31 Dec 16 | 1,743 | 153 | 248 | 0 |
| 30 Sep 16 | 1,648 | 157 | 242 | 0 |
| 30 Jun 16 | 1,503 | 130 | 233 | 0 |
| 31 Mar 16 | 1,433 | 119 | 227 | 0 |
| 31 Dec 15 | 1,369 | 101 | 223 | 0 |
| 30 Sep 15 | 1,315 | 88 | 214 | 0 |
| 30 Jun 15 | 1,289 | 83 | 211 | 0 |
| 31 Mar 15 | 1,287 | 91 | 214 | 0 |
| 31 Dec 14 | 1,276 | 94 | 211 | 0 |
| 30 Sep 14 | 1,235 | 82 | 209 | 0 |
| 30 Jun 14 | 1,197 | 87 | 202 | 0 |
| 31 Mar 14 | 1,160 | 71 | 197 | 0 |
| 31 Dec 13 | 1,130 | 61 | 194 | 0 |
| 30 Sep 13 | 1,101 | 54 | 191 | 0 |
| 30 Jun 13 | 1,077 | 35 | 192 | 0 |
Quality Earnings: VIH-R has high quality earnings.
Growing Profit Margin: VIH-R's current net profit margins (10.3%) are lower than last year (19%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VIH-R's earnings have grown significantly by 22.8% per year over the past 5 years.
Accelerating Growth: VIH-R's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: VIH-R had negative earnings growth (-59.2%) over the past year, making it difficult to compare to the Healthcare industry average (-29.6%).
Return on Equity
High ROE: VIH-R's Return on Equity (9.4%) is considered low.